Evidence map›Paper›PMID 36136177›Full record

ReviewCurrent treatment options in oncology2022

Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.

Ajay Dhakal, Amanda E D Van Swearingen, Ruth O'Regan, Carey K Anders

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ajay DhakalUniversity of Rochester, Rochester, NY, USA.
Amanda E D Van SwearingenDuke Center for Brain and Spine Metastasis, Duke Cancer Institute, Duke University, Durham, NC, USA.ORCID 0000-0002-4287-9741
Ruth O'ReganUniversity of Rochester, Rochester, NY, USA.
Carey K AndersDuke Center for Brain and Spine Metastasis, Duke Cancer Institute, Duke University, Durham, NC, USA. carey.anders@duke.edu.
Duke University · USUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementBrain metastasis arising from breast cancer is associated with a poor prognosis. Various systemic chemotherapy and targeted therapies which are effective against breast cancer often fail to provide benefits against brain metastasis. This is mainly due to limited penetration of the therapies across the blood-brain barrier, and divergent evolution of brain metastasis compared to the primary tumor. Thus, brain metastasis is typically treated upfront with local therapies, such as surgery and radiation, followed by systemic therapies. Systemic therapies with CNS permeability are favored in patients with brain metastasis. This paper reviews various systemic therapy options for breast cancer brain metastasis.

Indexed as

Brain NeoplasmsBreast NeoplasmsBlood-Brain BarrierFemaleHumansBrain metastasesBreast cancerHER2LeptomeningealSystemic therapyTriple negative

Identifiers

PMID36136177
OpenAlexW4296642581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.